Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer-Reference-Cited by-同舟云学术

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer

Published:2010-03-01 Issue:5 Volume:116 Page:1336-1343
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Young Joo,Choi Hye Jin,Kim Se Kyu,Chang Joon,Moon Jin Wook,Park In Kyu,Kim Joo-Hang,Cho Byoung Chul

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24877/fullpdf

Reference41 articles.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected];Fukuoka;J Clin Oncol.,2003

2. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA.,2003

3. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer;Perez-Soler;J Clin Oncol.,2004

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med.,2005

5. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence;Mitsudomi;J Clin Oncol.,2005

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L);JTO Clinical and Research Reports;2023-12

2. Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases;Brain Sciences;2023-09-03

3. Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors;Translational Lung Cancer Research;2023-06

4. Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer;Cancer Medicine;2023-04-25

5. Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study;Cancers;2023-03-03